|
|
Post by uvula on Dec 30, 2018 23:46:17 GMT -5
I'm pissed also but I'm willing to listen to Mike on Friday before I conclude that we all got screwed again.
|
|
|
|
Post by nylefty on Dec 30, 2018 23:55:16 GMT -5
Thanks Sports...can anyone tell me what we are getting in return for our 1.6M investment in Tross and Rose? There is no "1.6M investment" in those two. Matt explained this in another thread. mnkd.proboards.com/post/165583/thread |
|
|
|
Post by tz on Dec 31, 2018 0:10:26 GMT -5
I also don't understand deleting or suspending a Twitter account, wasnt a good move.. looks cowardly to me.. we need a strong CEO that doesn't run and hide.. We have been through the mill with this investment.. loyal.. trusting and defending Mike C. .. Good say. A CEO should have the vision to make good decision and the gut to execute. If Mike can not make it, he should resign. |
|
|
|
Post by tz on Dec 31, 2018 0:13:50 GMT -5
Guys on Wall Street are starting to talk about market liquidity drying up in the 4th quarter. That just might have had an impact on the timing here...maaaaybe. However, I see it as an overall good thing and I'll tell you why. In the brief two years Mike has been our CEO, he has impressed me with not only his pharmaceutical acumen but his sincerity, drive and, most importantly his business intellect. The debt restructuring, hands-on sales team management and complete transition of Mannkind from a R&D culture to a fully integrated top to bottom pharmaceutical company are commendable, to say the least. In his defense, the main theme of every foreword looking timeline slide this last year has been the 5 year plan. That's a subtle, even legal way of telling us it's going to take some more time. Besides, when the 280 million shares were authorized, what did everyone expect, really? We were about to be going defunct without it, as I recall. I certainly remember saying at the time that I'm going to figure total usage of those shares in my favorite pie-in-the-sky, back-of-the-napkin math. It just HAS to happen to succeed. Mike wouldn't do this unless he had good, clear positive usage for it. My only hope is we stop needing dilution by around 250 mil O/S, leaving 10-12% + the 10 million preferred shares to dangle as future buy-in bait. Oh, and we just yesterday had a 20% beat of our prior best weekly $ales number. Perhaps the advertising is starting to work and warrants further investment even if its temporarily dilutive. Accelerated revenue growth cures EVERYTHING quicker. JMHO Any defense to this dilution is weak, a very bad decision brings fear of liquidation to the company. No one will buy the stock again, including me. I will slowly sell off my shares. Forget it. Mike sucks. |
|
|
|
Post by longliner on Dec 31, 2018 0:29:30 GMT -5
Guys on Wall Street are starting to talk about market liquidity drying up in the 4th quarter. That just might have had an impact on the timing here...maaaaybe. However, I see it as an overall good thing and I'll tell you why. In the brief two years Mike has been our CEO, he has impressed me with not only his pharmaceutical acumen but his sincerity, drive and, most importantly his business intellect. The debt restructuring, hands-on sales team management and complete transition of Mannkind from a R&D culture to a fully integrated top to bottom pharmaceutical company are commendable, to say the least. In his defense, the main theme of every foreword looking timeline slide this last year has been the 5 year plan. That's a subtle, even legal way of telling us it's going to take some more time. Besides, when the 280 million shares were authorized, what did everyone expect, really? We were about to be going defunct without it, as I recall. I certainly remember saying at the time that I'm going to figure total usage of those shares in my favorite pie-in-the-sky, back-of-the-napkin math. It just HAS to happen to succeed. Mike wouldn't do this unless he had good, clear positive usage for it. My only hope is we stop needing dilution by around 250 mil O/S, leaving 10-12% + the 10 million preferred shares to dangle as future buy-in bait. Oh, and we just yesterday had a 20% beat of our prior best weekly $ales number. Perhaps the advertising is starting to work and warrants further investment even if its temporarily dilutive. Accelerated revenue growth cures EVERYTHING quicker. JMHO Any defense to this dilution is weak, a very bad decision brings fear of liquidation to the company. No one will buy the stock again, including me. I will slowly sell off my shares. Forget it. Mike sucks. Good luck with your other investments tz! Happy New Year. |
|
|
|
Post by longliner on Dec 31, 2018 0:34:25 GMT -5
I feel like I'm getting told a bunch of shit just to string me along. Tired of it.. I love Afrezza.. know that it's the best meal time insulin out there.. but also knew what we were up against a long time ago.. kept the faith in new management up until now.. now I'm pissed.. especially when I hear management is taking trips to Hawai after this.. not good!!!!! I'm out in the middle of ND and it's blizzarding.. LOL .. granted I'm at a beautiful lodge and it's my son's wedding. but still.. Congratulations! This is a stressful time for you for the right reasons. Focus on what matters to you, the rest will work itself out. I share your blizzard but not (yet) the wedding. |
|
|
|
Post by porkini on Dec 31, 2018 1:08:47 GMT -5
Unfortunately Mike C has very little skin in the game....the more dilution that happens means more money for him to work with. Sure the company turns around but shareholders get slammed in the process. He reports to CURRENT shareholders and should hold CURRENT shareholder value in his highest regard.....not the future shareholders who will be there to benefit from current longs. Oh, really? Prove it. No, really, prove it! And, by whose standard are you using "very little skin in the game"? Were you thinking that he could single-handedly purchase the entire company or something? I'm guessing that Mike C has more skin in the game than most of the whiners on the internet. That was pretty non-descript, "whiners on the internet," jeepers, proud of myself for that. Surprised someone else has not challenged this already, utterly ridiculous! |
|
|
|
Post by longliner on Dec 31, 2018 1:32:00 GMT -5
Unfortunately Mike C has very little skin in the game....the more dilution that happens means more money for him to work with. Sure the company turns around but shareholders get slammed in the process. He reports to CURRENT shareholders and should hold CURRENT shareholder value in his highest regard.....not the future shareholders who will be there to benefit from current longs. Oh, really? Prove it. No, really, prove it! And, by whose standard are you using "very little skin in the game"? Were you thinking that he could single-handedly purchase the entire company or something? I'm guessing that Mike C has more skin in the game than most of the whiners on the internet. That was pretty non-descript, "whiners on the internet," jeepers, proud of myself for that. Surprised someone else has not challenged this already, utterly ridiculous! To add to Porkini's well placed response to Winstonsmith, anyone with good charactor, (as I believe Mike possesses), has a great deal more to lose in self respect than the average shareholder, should Mannkind fail. (Mike represents Alfred Mann's legacy as well as Wharton) if he fails patients and shareholders in the many lifesaving medical advancement's technosphere offers it will certainly prove to have been "skin in the game" for him. |
|
|
|
Post by slugworth008 on Dec 31, 2018 4:33:37 GMT -5
The only 2 I take issue with is Matthew J. Pfeffer (still on the payroll really?) and Tross. |
|
|
|
Post by boca1girl on Dec 31, 2018 8:23:53 GMT -5
The only 2 I take issue with is Matthew J. Pfeffer (still on the payroll really?) and Tross. Look at the dates. That was for 2017, not 2018. |
|
|
|
Post by barnstormer on Dec 31, 2018 9:07:36 GMT -5
As a long time burned shareholder I agree with most of the comments here. Mike had an opportunity a year ago to get Afrezza distributed in UAE. When asked at the ASM what happened he said he would have had to deal with too many players. Perhaps he should have hired someone to do that for him. To me it was a bird in the hand and a willing partner with a huge market. Now he doesn't even speak of distribution there. He struck a deal with BIOMM with no cash & apparently no timeline for them to perform. Granted they have to deal with the approval agency in Brazil, but there is never any progress to report. Cipla is the same only in India. They should be reporting progress to him and he could at least give shareholders a rough idea of where Cipla is in the process and what a worstcase/bestcase time frame could be achieved. Tanner? Same thing. Nothing. If any of these deals hold water then some progress should be reported. Are all of these companies free from progress milestones without penalty? They should be jumping through hoops for access to Afrezza. These deals smack of the same poor structure as the offering. I would hope Mike enlightens us about the status of these and other objectives on the call or it isn't worth opening up the conference bridge.
|
|
|
|
Post by agedhippie on Dec 31, 2018 10:05:30 GMT -5
As a long time burned shareholder I agree with most of the comments here. Mike had an opportunity a year ago to get Afrezza distributed in UAE. When asked at the ASM what happened he said he would have had to deal with too many players. Perhaps he should have hired someone to do that for him. To me it was a bird in the hand and a willing partner with a huge market. Now he doesn't even speak of distribution there. He struck a deal with BIOMM with no cash & apparently no timeline for them to perform. Granted they have to deal with the approval agency in Brazil, but there is never any progress to report. Cipla is the same only in India. They should be reporting progress to him and he could at least give shareholders a rough idea of where Cipla is in the process and what a worstcase/bestcase time frame could be achieved. Tanner? Same thing. Nothing. If any of these deals hold water then some progress should be reported. Are all of these companies free from progress milestones without penalty? They should be jumping through hoops for access to Afrezza. These deals smack of the same poor structure as the offering. I would hope Mike enlightens us about the status of these and other objectives on the call or it isn't worth opening up the conference bridge. There was guidance on progress: Our Afrezza international expansion is well underway, with Brazil expecting approval in Q4, and India progressing in a phase 3 trial for filing there, as well as Mexico and Canada we continue to work towards.I guess the Q4 approval was a miss, but in fairness he had said earlier at the Rodman & Renshaw conference that the Brazil launch would be Q1. I thought at some point he had said H2 for India but I cannot find that now. There will not be anything to report for Tanner as they are a distribution rather than sales org. Why would they jump through hoops for Afrezza? They have to do all the regulatory work in their country, and then sell it. That's quite a big ask all on it's own. Start increasing the risk further by setting penal targets and they would just walk away. If Afrezza was a blockbuster in the US it would be different. |
|
|
|
Post by mnholdem on Dec 31, 2018 11:03:20 GMT -5
There's an axiom that states "Achieving a major objective with poor planning will take 3-4 times longer than you expect. With good planning it will only take twice as long."  |
|
|
|
Post by peppy on Dec 31, 2018 11:14:34 GMT -5
As a long time burned shareholder I agree with most of the comments here. Mike had an opportunity a year ago to get Afrezza distributed in UAE. When asked at the ASM what happened he said he would have had to deal with too many players. Perhaps he should have hired someone to do that for him. To me it was a bird in the hand and a willing partner with a huge market. Now he doesn't even speak of distribution there. He struck a deal with BIOMM with no cash & apparently no timeline for them to perform. Granted they have to deal with the approval agency in Brazil, but there is never any progress to report. Cipla is the same only in India. They should be reporting progress to him and he could at least give shareholders a rough idea of where Cipla is in the process and what a worstcase/bestcase time frame could be achieved. Tanner? Same thing. Nothing. If any of these deals hold water then some progress should be reported. Are all of these companies free from progress milestones without penalty? They should be jumping through hoops for access to Afrezza. These deals smack of the same poor structure as the offering. I would hope Mike enlightens us about the status of these and other objectives on the call or it isn't worth opening up the conference bridge. There was guidance on progress: Our Afrezza international expansion is well underway, with Brazil expecting approval in Q4, and India progressing in a phase 3 trial for filing there, as well as Mexico and Canada we continue to work towards.I guess the Q4 approval was a miss, but in fairness he had said earlier at the Rodman & Renshaw conference that the Brazil launch would be Q1. I thought at some point he had said H2 for India but I cannot find that now. There will not be anything to report for Tanner as they are a distribution rather than sales org. Why would they jump through hoops for Afrezza? They have to do all the regulatory work in their country, and then sell it. That's quite a big ask all on it's own. Start increasing the risk further by setting penal targets and they would just walk away. If Afrezza was a blockbuster in the US it would be different.aged, compared to the old and lousy chit you are injecting into the subq fat tissue you can muster, afrezza is a block buster. Insulin is an expensive medication. Publicly traded for profit Insurance companies have contracts for Pharma milestone rebates. And a profit model limiting insurance coverage, and physician participation. Scripts are moving up. continuous glucose monitors are going to save afrezza. There is a LADA diagnosed every day. |
|
|
|
Post by sportsrancho on Dec 31, 2018 11:17:04 GMT -5
|
|
